Annovis Reports 2025 Results, Advances Buntanetap Trials
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) reported its 2025 financial results and said it advanced late-stage clinical development of its investigational drug buntanetap, including launching a Phase 3 …
Annovis Reports 2025 Results, Advances Buntanetap Trials Read More